Literature DB >> 15287403

Prophylaxis for heterotopic ossification after primary total hip arthroplasty. A cohort study between indomethacin and meloxicam.

Huub J L van der Heide1, Maarten Spruit, Rob Slappendel, Niels Klooster, Jacques van Limbeek.   

Abstract

The authors have conducted a prospective cohort study of the efficacy of a 7 days administration of Indomethacin (n = 89) versus Meloxicam (n = 92), in the prophylaxis of heterotopic ossification (HO) in primary total hip arthroplasty. To assess the interobserver variability of the Brooker classification, all radiographs were evaluated by three investigators. In the Indomethacin group 25 patients developed HO (grade I: 22, grade III: 2 and grade IV: 1). In the Meloxicam group 34 developed HO (grade I: 30, grade II: 1 and grade III: 3). We were not able to show any difference between Indomethacin and Meloxicam in preventing heterotopic ossification after primary hip arthroplasty. We found a high interobserver variability in the grading system according to Brooker, in particular for the higher grades(grade II, III and IV).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15287403

Source DB:  PubMed          Journal:  Acta Orthop Belg        ISSN: 0001-6462            Impact factor:   0.500


  6 in total

1.  Comparative clinical study of the prophylaxis of heterotopic ossifications after total hip arthroplasty using etoricoxib or diclofenac.

Authors:  Sebastian Winkler; Hans-Robert Springorum; Tobias Vaitl; Martin Handel; Sabine Barta; Victoria Kehl; Benjamin Craiovan; Joachim Grifka
Journal:  Int Orthop       Date:  2016-01-04       Impact factor: 3.075

2.  Selective versus non-selective NSAIDs as prophylaxis for heterotopic ossification following hip arthroplasty: a meta-analysis.

Authors:  Filippo Migliorini; Andrea Pintore; Alice Baroncini; Torsten Pastor; Frank Hildebrand; Nicola Maffulli
Journal:  J Orthop Traumatol       Date:  2022-07-09

3.  Preoperative meloxicam versus postoperative meloxicam for pain control, patients' satisfaction and function recovery in hip osteoarthritis patients who receive total hip arthroplasty: a randomized, controlled study.

Authors:  Lingyun Ren; Li Meng; Hong Yan; Wei Sun; Dan Yao
Journal:  Inflammopharmacology       Date:  2020-06-06       Impact factor: 4.473

4.  Prophylaxis of heterotopic ossification - an updated review.

Authors:  Evan O Baird; Qian K Kang
Journal:  J Orthop Surg Res       Date:  2009-04-20       Impact factor: 2.359

Review 5.  Selective COX-2 inhibitor versus non-selective COX-2 inhibitor for the prevention of heterotopic ossification after total hip arthroplasty: A meta-analysis.

Authors:  Xi-Tian Zhu; Lei Chen; Jian-Hua Lin
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

6.  NSAIDs for Prophylaxis for Heterotopic Ossification After Total Hip Arthroplasty: A Bayesian Network Meta-analysis.

Authors:  Filippo Migliorini; Andromahi Trivellas; Jörg Eschweiler; Arne Driessen; Markus Tingart; Nicola Maffulli
Journal:  Calcif Tissue Int       Date:  2020-10-12       Impact factor: 4.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.